In line with this, the National Comprehensive Cancer Network (NCCN) clinical practice guidelines recommend semi-annual abdominal ultrasound and alpha-fetoprotein (AFP) screening for individuals at high risk of HCC, especially those with cirrhosis of any etiology, to closely monitor disease progression.10 This evidence concerns the gene AFP and Cirrhosis.